SCHEMBL1676436

SCHEMBL1676436

FC(F)(F)c1cccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4)c[nH]3)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.41
IDO1 P14902 1/20 0.39
CYP3A4 P08684 2/20 0.39
CYP17A1 P05093 1/20 0.39
PTGES O14684 1/20 0.39
KDM1A O60341 2/20 0.38
XDH P47989 1/20 0.38
TRPM2 O94759 1/20 0.38
NFE2L2 Q16236 1/20 0.38
ERBB2 P04626 2/20 0.38
CTSS P25774 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 2/20 0.37
HPGD P15428 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676433 1.00 VCP (0.41) VCPIDO1CYP3A4CYP17A1PTGES
SCHEMBL1676409 0.92 TRPM2 (0.44) IDO1XDHTRPM2NFE2L2ERBB2
SCHEMBL1676406 0.92 TRPM2 (0.44) IDO1XDHTRPM2NFE2L2ERBB2
SCHEMBL1676532 0.89 DPP4 (0.43) IDO1CYP3A4PTGESKDM1AXDH
SCHEMBL1676530 0.89 DPP4 (0.43) IDO1CYP3A4PTGESKDM1AXDH
SCHEMBL1676276 0.88 PTGES (0.40) IDO1CYP3A4PTGESKDM1AXDH
SCHEMBL1676272 0.88 PTGES (0.40) IDO1CYP3A4PTGESKDM1AXDH
SCHEMBL1677182 0.86 RORC (0.42) IDO1PTGESKDM1AXDHTRPM2
SCHEMBL1677183 0.86 RORC (0.42) IDO1PTGESKDM1AXDHTRPM2
SCHEMBL1482109 0.84 IDO1 (0.42) IDO1KDM1AXDHNFE2L2CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE VCP 2107/4885IDO1 500/4885CYP3A4 583/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE VCP 2107/4885IDO1 500/4885CYP3A4 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.